EMA Recommends Adapted Spikevax Vaccine
The agency has recommended authorization of the Spikevax COVID-19 vaccine that targets the Omicron variants BA.4 and BA.5.
The European Medicines Agency announced on Oct. 19, 2022 that its Committee for Medicinal Products for Human Use (CHMP) has recommended the authorization of the adapted Spikevax COVID-19 vaccine. The new vaccine targets the Omicron subvariants BA.4 and BA.5 and the original strain of SARS-CoV-2. The recommendation is for use in adults and children 12 years and older who have already received a primary vaccination course against COVID-19.
CHMP took into account available data on the Spikevax vaccine and the authorized Spikevax bivalent Original/Omicron BA.1. According to EMA, both adapted vaccines have the same composition. The decision by CHMP was also based on the quality and manufacturing process that meets quality standards in the European Union. Non-clinical laboratory data also showed that the adapted vaccine triggered an adequate immune response.
“Based on all these data and the similar composition of the adapted vaccines, the CHMP concluded that Spikevax bivalent Original/Omicron BA.4-5 is expected to be more effective than the originally authorized vaccine at triggering an immune response against the BA.4 and BA.5 subvariants. The vaccine’s safety profile is expected to be comparable to that of Spikevax bivalent Original/Omicron BA.1 and the originally authorized Spikevax, for which a large amount of data is available,” the agency stated in a press release.
The opinion now goes to the European Commission for final adoption.
Source: EMA
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
New Cancer Research and Treatment Center in Development in London
May 1st 2025Aviva Capital Partners and developer Socius are investing £1 billion in a 12-acre site to be located at the London Cancer Hub next to The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust’s Sutton site.
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
